Testosterone Replacement Therapy: What to Expect
Testosterone replacement therapy (TRT) is an FDA-approved treatment for men with clinically confirmed hypogonadism — meaning documented low testosterone levels combined with symptoms. If you and your doctor have determined that TRT is appropriate, understanding the treatment options and what to expect helps you make informed decisions and monitor your progress effectively.
Forms of TRT
Topical gels and creams are the most commonly prescribed form. Applied daily to the shoulders, upper arms, or abdomen, they provide stable levels without the peaks and troughs of injections. The main drawback is transfer risk to partners and children through skin contact, requiring care with application sites and timing.
Intramuscular injections (testosterone cypionate or enanthate) are typically self-administered every 1-2 weeks or weekly. They are effective and inexpensive, but produce peaks (immediately after injection) and troughs (just before the next dose), which some men find creates mood and energy fluctuations. Subcutaneous injections are increasingly used as an alternative with smoother levels.
Transdermal patches provide daily delivery but can cause skin irritation at the application site. Buccal systems adhere to the gum twice daily. Testosterone pellets — implanted under the skin of the buttock every 3-6 months — offer the most consistent delivery without daily or weekly adherence requirements.
Clomiphene citrate is not testosterone but a selective estrogen receptor modulator (SERM) that stimulates the body's own testosterone production by signaling the pituitary to release more LH. It is often preferred in younger men who want to preserve fertility, as exogenous testosterone suppresses sperm production.
Expected Benefits
With appropriate TRT in genuinely hypogonadal men: improved energy and reduced fatigue (often within 3-6 weeks), improved libido and sexual function (3-6 weeks to months), improved mood and reduced depression symptoms (3-6 weeks), increased muscle mass and reduced fat mass (3-6 months), and improved bone density (6-12+ months). Not all men respond to the same degree, and results depend on other health factors.
Risks and Monitoring
TRT increases red blood cell production (erythrocytosis), raising blood thickness and clot risk in some men — monitored with regular hematocrit blood tests. It does not cause prostate cancer but can stimulate growth of existing prostate tissue; PSA and prostate assessment are part of monitoring. Cardiovascular effects are complex: current evidence is mixed, and TRT should be used cautiously in men with recent cardiovascular events. Regular monitoring of testosterone, hematocrit, PSA, lipids, and estradiol is standard of care.
Visit our resources for provider directories or read about recognizing low T symptoms to see if TRT evaluation is appropriate for you.